TAVNEOS, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)2

TAVNEOS should be initiated and monitored by healthcare professionals experienced in the diagnosis and treatment of GPA or MPA2

TAVNEOS-based regimen

Efficacy

achieved non-inferior clinical remission at Week 26 and superior sustained clinical remission at Week 52 vs a
GC-based regimen1*

EFFICACY
Efficacy

resulted in a lower absolute risk of relapse vs a GC-based regimen over 52 weeks1

EFFICACY
Efficacy

demonstrated sustained improvement in renal function over 1 year vs a GC-based regimen1

RENAL FUNCTION
Efficacy

allowed physicians to reduce GC use with a signicant reduction in GC toxicity vs a GC-based regimen1,5

GC TOXICITY
Efficacy

demonstrated signicant improvements in physical and health-related domains of QoL vs a GC-based regimen1,6†‡

QUALITY OF LIFE
Efficacy

includes TAVNEOS taken as a fixed oral dose with no additional monitoring beyond standard disease management2§

SAFETY & DOSING
Efficacy

TAVNEOS demonstrated a favourable safety profile1

SAFETY & DOSING
Efficacy

TAVNEOS is the first targeted treatment for AAV already recognised in the EULAR 2022 recommendations3,4,7

INNOVATIVE MOA

Introducing TAVNEOS: a first-in-class targeted treatment for GPA/MPA

Discover how to use TAVNEOS

*Clinical remission in the ADVOCATE study was dened as a BVAS 0 and no glucocorticoid use in previous 4 weeks.1

†A numerical improvement was seen in mental QoL.6

‡With the EQ-5D-5L index, numerical improvements were observed at Week 26, and signicant improvements were observed at Week 52 (p=0.009) in the TAVNEOS-based regimen vs GC-based regimen.6

§TAVNEOS is administered as a xed dose regimen, and it is not necessary to monitor organ impairment and undertake additional analysis beyond what is needed for standard disease management. Hepatic enzymes, total bilirubin and white blood cell count must be monitored.2Please consult the Summary of Product Characteristics for further information.

AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; EQ-5D-5L, EuroQoL-5 dimension-5 level; EULAR, European Alliance of Associations for Rheumatology; GC, glucocorticoid; GPA, granulomatosis with polyangiitis; MOA, mechanism of action; MPA, microscopic polyangiitis; QoL, quality of life.

1. Jayne D, et al. N Engl J Med 2021;384(7):599–609. 2. TAVNEOS EU SmPC July 2023. 3. Bekker P, et al. PLoS One 2016;11(10):e0164646. 4. European Medicine Agency (2021). First-in-class medicine recommended for treatment of rare blood vessel inflammation. Available at: https://www.ema.europa.eu/en/news/first-class-medicine-recommended-treatment-rare-blood-vessel-inflammation. Date accessed: August 2023. 5. Stone J, et al. Semin Arthritis Rheum 2022;55:152010. 6. Vifor Pharma (2020). Data on File. 7. Hellmich B, et al. Ann Rheum Dis 2023;0:1–18.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.